国内外药企竞相布局合胞病毒疫苗

北京商报
Oct 13, 2025

近日,国内外制药企业正在呼吸道合胞病毒(RSV)预防与治疗领域积极布局。截至目前,全球已有三款RSV预防药物获批上市,其中,已在国内获批的有尼塞韦单抗一款。该单抗系阿斯利康与赛诺菲联合开发,价格不菲,适用于5kg以上儿童的剂型价格超过3000元。此外,国内当前也有多家药企布局RSV相关药物研发,包括珠海泰诺麦博制药股份有限公司(以下简称“泰诺麦博”)的TNM001、智翔金泰的GR2102注射液等。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10